Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
7.5
Expiration
Dec 11, 2026
DTE
28d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $1.50 | +0.00% | 1 | 505 |
| Nov 20, 2026 | 7d | $1.27 | +0.00% | 45 | 329 |
| Nov 27, 2026 | 14d | $1.35 | -27.42% | 50 | 168 |
| Dec 4, 2026 | 21d | $1.51 | -13.71% | 11 | 81 |
| Dec 11, 2026 | 28d | $1.58 | +0.00% | 12 | 34 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $1.77 | -23.04% | 25 | 21,172 |
| Jan 21, 2028 | 434d | $3.14 | -6.82% | 6 | 18,082 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.